查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679414

醫藥市場規模、佔有率和趨勢分析報告：按分子類型、產品類型、疾病、年齡層、給藥途徑、分銷管道、地區、細分趨勢，2025-2030 年

Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Age Group, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 250 Pages | 商品交期: 2-10個工作天內

價格

醫藥市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，到2030年全球醫藥市場規模預計將達到23,504.3億美元，預計2025年至2030年的複合年成長率為6.12%。

醫藥市場的成長是由慢性病日益流行的推動的，這推動了開發新型治療方法的需求。根據美國國家老齡委員會估計，大約 95% 的老年人患有至少一種慢性病，大約 80% 的老年人患有兩種或兩種以上的慢性病。此外，糖尿病、關節炎和心臟病等慢性疾病對老年人的影響尤其嚴重。

意識是預防、早期發現、有針對性的照護和有效治療的關鍵。了解疾病及其症狀的人更有可能採取預防措施，如篩檢、測試和身體檢查。人們對各種疾病的認知不斷提高也是製藥業發展的促進因素之一。現在人們對癌症和糖尿病等疾病的認知有所提高，一旦患上這些疾病，他們就更有可能尋求治療。公共和私人組織正在採取各種措施來傳播意識並教育公眾。此外，越來越多的人購買保險來支付處方藥費用，增加了藥品需求。

此外，新療法開發技術的進步導致全球對藥品的需求大幅增加。製藥業在研發以及產品銷售和分銷方面的投資比以往任何時候都多。這個行業專注於明確和直接地解決人們的健康問題。製藥業對患者護理和社區發展至關重要，提供無數挽救生命的治療，創造就業機會並為全球經濟做出貢獻。

許多生技藥品，包括細菌和病毒，都用於疫苗生產、發酵過程和生物技術。該市場由各種各樣的公司組成，包括大型製藥公司、中型專業製藥公司、虛擬製藥公司、非專利製造商以及小型生物技術和生物製藥公司。此外，參與開發和配製各種治療製劑的主要參與企業正在加強合作和夥伴關係，以開發新藥並保持市場競爭力。

此外，一些公司正在致力於開發新藥，以滿足日益成長的預防和治療該疾病的需求。例如，2023年4月，羅氏公司宣布，其治療濕性老齡化黃斑部病變的藥物Vabysmo（該藥物於2022年1月獲得FDA核准）在2023年第一季的銷售額約為5億美元，同比成長超過500%，超過了多發性硬化症治療藥物Ocrevus和血友病藥物。此外，2023年7月，諾華公司獲得美國FDA批准，擴大Rekmeo（通用名：inclisiran）的核准，包括治療高LDL-C水平且患有心臟病風險高的患者。

醫藥市場報告重點

  • 到 2024 年，傳統藥物（小分子）將佔據市場主導地位，銷售額佔 54.74%。
  • 品牌藥將主導醫藥市場，到 2024 年銷售額將佔 86.76%。
  • 由於慢性病治療需求的不斷成長、藥物開發技術的進步以及醫療保健管道的改善，處方箋部分在 2024 年佔據了市場主導地位，收入佔有率達到 86.76%。
  • 2024 年，腫瘤學領域佔據市場主導地位，收入佔有率為 18.06%。
  • 口服製劑領域佔據胜肽藥物結合物市場的主導地位，由於其便利性、患者依從性和成本效益，2024 年的收益佔有率為 57.53%。
  • 在胜肽藥物偶聯物市場中，成人市場在 2024 年佔據 63.84% 的收入佔有率。
  • 醫院藥局部門在胜肽結合物市場佔據主導地位，2024 年的收入佔有率為 53.53%。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章醫藥市場變數、趨勢和範圍

  • 母市場展望
  • 補貼市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 多巴胺促效劑分析工具
    • 波特的分析
    • PESTEL分析
  • 管道分析
    • 第一階段
    • 第 2 階段
    • 第 3 階段

第4章：醫藥市場：依藥物的估計與趨勢分析

  • 醫藥市場：藥品細分儀表板
  • 醫藥市場：藥物趨勢分析（百萬美元），2024 年與 2030 年
  • 生技藥品和生物相似藥（聚合物）
    • 單株抗體
    • 疫苗
    • 細胞和基因治療
    • 其他
  • 常規藥物（小分子）

第5章：醫藥市場類型、估價與趨勢分析

  • 醫藥市場：型細分儀表板
  • 醫藥市場：類型變化分析，百萬美元，2024 年與 2030 年
  • 處方藥
  • 非處方藥

第6章：醫藥市場：產品特定、估計與趨勢分析

  • 醫藥市場：產品細分儀表板
  • 醫藥市場：產品差異分析，百萬美元，2024 年對比 2030 年
  • 品牌
  • 非專利的

第7章：醫藥市場：特定疾病、估計與趨勢分析

  • 醫藥市場：疾病細分儀表板
  • 醫藥市場：疾病趨勢分析（百萬美元），2024 年和 2030 年
  • 心血管疾病
  • 癌症
  • 糖尿病
  • 感染疾病
  • 神經系統疾病
  • 呼吸系統疾病
  • 自體免疫疾病
  • 精神疾病
  • 胃腸道疾病
  • 女性健康疾病
  • 遺傳疾病及罕見遺傳疾病
  • 皮膚病
  • 肥胖
  • 腎臟疾病
  • 肝臟疾病
  • 血液系統疾病
  • 眼部疾病
  • 不孕不育
  • 內分泌失調
  • 過敏
  • 其他

第 8 章：按給藥途徑分類的藥品市場、估計和趨勢分析

  • 醫藥市場：細分儀表板
  • 醫藥市場：給藥途徑變化分析，百萬美元，2024 年與 2030 年
  • 口服
    • 錠劑
    • 膠囊
    • 暫停
    • 其他
  • 局部的
  • 腸外
    • 靜脈
    • 肌肉注射
  • 吸入
  • 其他

第9章：醫藥市場：依年齡層別估計和趨勢分析

  • 醫藥市場：年齡層細分儀表板
  • 醫藥市場：年齡人口統計分析，百萬美元，2024 年和 2030 年
  • 兒童和青少年
  • 成人
  • 老年人

第 10 章：醫藥市場：按分銷管道分類的估計和趨勢分析

  • 醫藥市場：通路細分儀表板
  • 醫藥市場：通路變化分析（百萬美元），2024 年比較 2030 年
  • 醫院藥房
  • 零售藥局
  • 其他

第 11 章醫藥市場：區域、估計與趨勢分析

  • 2024 年及 2030 年各地區醫藥市場佔有率（百萬美元）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第12章競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 參與者概述
  • 產品基準
  • 2024年公司市場佔有率分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • AbbVie Inc.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi
    • GlaxoSmithKline plc.
    • AstraZeneca
    • Takeda Pharmaceutical Co., Ltd.

第13章 結論

Product Code: GVR-4-68040-159-7

Pharmaceutical Market Growth & Trends:

The global pharmaceutical market size is estimated to reach USD 2,350.43 billion by 2030, registering to grow at a CAGR of 6.12% from 2025 to 2030 according to a new report by Grand View Research, Inc. The growth of the pharmaceuticals market is attributable to the increasing prevalence of chronic diseases, leading to a growing need for developing novel therapeutics. According to the National Council on Aging, it is estimated that approximately 95% of the older population has at least one chronic ailment, and around 80% has two or more. Moreover, chronic diseases such as diabetes, arthritis, and heart disease disproportionately affect the elderly population.

Awareness is critical for prevention, early detection, focused therapy, and effective treatment. People aware of an illness and its symptoms are more inclined to take preventative measures, such as screenings, tests, and check-ups. The increased awareness of various diseases is another element driving the pharmaceutical space. As people are now aware of diseases such as cancer and diabetes, they are more likely to seek treatment if they develop those conditions. A number of initiatives are taken by public and private organizations to spread awareness and educate the population. Furthermore, many people now have insurance policies that cover prescription drug expenses, contributing to increased pharmaceutical demand.

Moreover,the demand for pharmaceuticals is significantly increasing globally due to advancements in technology in the development of novel therapeutics. The pharmaceutical industry invests at an unprecedented rate in research and development, as well as product sales and distribution. The industry focuses on distinctly and directly addressing people's health. The pharmaceuticals industry is critical to patient care and community development and provides numerous life-saving treatments, generates employment, and contributes to the world economy.

Many biological agents, such as bacteria and viruses, are used in vaccine manufacturing, fermentation processes, and biotechnology. The market is made up of a diverse spectrum of companies, including giant pharma, mid-sized specialty, virtual pharma, generic manufacturers, and small biotechnology and biopharmaceutical organizations. Furthermore, key players involved in developing and formulating various therapeutic formulations are focusing on collaborations and partnerships to develop novel medications and maintain their competitive position in the market.

Moreover, several players are involved in developing novel pharmaceuticals to meet the rising demand for the prevention and treatment of conditions. For instance, in April 2023, F. Hoffmann-La Roche Ltd. announced that its wet age-related macular degeneration drug, Vabysmo, which received FDA approval in January 2022, brought around USD 500 million during the first quarter of 2023. The drug's sales increased by more than 500% year-on-year, beating competitors such as multiple sclerosis treatment Ocrevus and the hemophilia medication Hemlibra. Moreover, in July 2023, Novartis AG received U.S. FDA approval for an expanded indication of Leqvio (inclisiran), in order to include treatment of patients with high LDL-C who are at an increased risk of heart diseases.

Pharmaceutical Market Report Highlights:

  • The Conventional drugs (small molecules) dominated the market with a revenue share of 54.74% in 2024.
  • The branded segment dominated the pharmaceutical market with a revenue share of 86.76% in 2024.
  • The prescription segment dominated the market with a revenue share of 86.76% in 2024 due to rising demand for chronic disease treatments, technological advancements in drug development, and improved healthcare access.
  • The cancer segment dominated the market with a revenue share of 18.06% in 2024.
  • The oral segment dominated the peptide drug conjugates market with a revenue share of 57.53% in 2024 due to its convenience, patient compliance, and cost-effectiveness.
  • The adults segment dominated the peptide drug conjugates market with a revenue share of 63.84% in 2024.
  • The hospital pharmacy segment dominated the peptide drug conjugates market with a revenue share of 53.53% in 2024

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmaceutical Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Advancement in therapeutics and robust product pipeline
      • 3.3.1.2. Rise in pharmaceutical r&d spending
      • 3.3.1.3. Rise in pharmaceutical r&d spending
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Patent expiration of key market drugs
      • 3.3.2.2. Pricing pressures on bio/pharmaceutical companies
      • 3.3.2.3. Stringent regulatory scenario
  • 3.4. Dopamine Agonist Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
  • 3.5. Pipeline Analysis
    • 3.5.1. Phase 1
    • 3.5.2. Phase 2
    • 3.5.3. Phase 3

Chapter 4. Pharmaceutical Market: By Drug Estimates & Trend Analysis

  • 4.1. Pharmaceutical Market: Drug Segment Dashboard
  • 4.2. Pharmaceutical Market: By Drug Movement Analysis, USD Million, 2024 & 2030
  • 4.3. Biologics & Biosimilars (Large Molecules)
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Monoclonal Antibodies
      • 4.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Vaccines
      • 4.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Cell & Gene Therapy
      • 4.3.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Conventional Drugs (Small Molecules)
    • 4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Market: Type Estimates & Trend Analysis

  • 5.1. Pharmaceutical Market: Type Segment Dashboard
  • 5.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
  • 5.3. Prescription
    • 5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. OTC
    • 5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pharmaceutical Market: Product Estimates & Trend Analysis

  • 6.1. Pharmaceutical Market: Product Segment Dashboard
  • 6.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
  • 6.3. Branded
    • 6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Generics
    • 6.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmaceutical Market: Disease Estimates & Trend Analysis

  • 7.1. Pharmaceutical Market: Disease Segment Dashboard
  • 7.2. Pharmaceutical Market: By Disease Movement Analysis, USD Million, 2024 & 2030
  • 7.3. Cardiovascular diseases
    • 7.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Cancer
    • 7.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Diabetes
    • 7.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Infectious diseases
    • 7.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Neurological disorders
    • 7.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Respiratory diseases
    • 7.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9. Autoimmune diseases
    • 7.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10. Mental health disorders
    • 7.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11. Gastrointestinal disorders
    • 7.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.12. Women's Health Diseases
    • 7.12.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.13. Genetic and Rare genetic diseases
    • 7.13.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.14. Dermatological conditions
    • 7.14.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.15. Obesity
    • 7.15.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.16. Renal diseases
    • 7.16.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.17. Liver conditions
    • 7.17.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.18. Hematological disorders
    • 7.18.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.19. Eye conditions
    • 7.19.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.20. Infertility conditions
    • 7.20.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.21. Endocrine disorders
    • 7.21.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.22. Allergies
    • 7.22.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.23. Others
    • 7.23.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Pharmaceutical Market: Route of Administration Segment Dashboard
  • 8.2. Pharmaceutical Market: By Route of Administration Movement Analysis, USD Million, 2024 & 2030
  • 8.3. Oral
    • 8.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Tablets
    • 8.3.3. Capsules
    • 8.3.4. Suspensions
    • 8.3.5. Other
  • 8.4. Topical
    • 8.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Parenteral
    • 8.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Intravenous
    • 8.5.3. Intramuscular
  • 8.6. Inhalations
    • 8.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Other Routes of Administration
    • 8.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Pharmaceutical Market: Age Group Estimates & Trend Analysis

  • 9.1. Pharmaceutical Market: Age Group Segment Dashboard
  • 9.2. Pharmaceutical Market: By Age Group Movement Analysis, USD Million, 2024 & 2030
  • 9.3. Children & Adolescents
    • 9.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Adults
    • 9.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Geriatric
    • 9.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Pharmaceutical Market: Distribution Channel Estimates & Trend Analysis

  • 10.1. Pharmaceutical Market: Distribution Channel Segment Dashboard
  • 10.2. Pharmaceutical Market: By Distribution Channel Movement Analysis, USD Million, 2024 & 2030
  • 10.3. Hospital Pharmacy
    • 10.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4. Retail Pharmacy
    • 10.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5. Others
    • 10.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 11. Pharmaceutical Market: Regional Estimates & Trend Analysis

  • 11.1. Pharmaceutical Market Share, By Region, 2024 & 2030, USD Million
  • 11.2. North America
    • 11.2.1. North America Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.2.2. U.S.
      • 11.2.2.1. Key Country Dynamics
      • 11.2.2.2. Target Disease Prevalence
      • 11.2.2.3. Regulatory Framework
      • 11.2.2.4. Reimbursement Framework
      • 11.2.2.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.2.3. Canada
      • 11.2.3.1. Key Country Dynamics
      • 11.2.3.2. Target Disease Prevalence
      • 11.2.3.3. Regulatory Framework
      • 11.2.3.4. Reimbursement Framework
      • 11.2.3.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.2.4. Mexico
      • 11.2.4.1. Key Country Dynamics
      • 11.2.4.2. Target Disease Prevalence
      • 11.2.4.3. Regulatory Framework
      • 11.2.4.4. Reimbursement Framework
      • 11.2.4.5. Mexico Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3. Europe
    • 11.3.1. Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.2. UK
      • 11.3.2.1. Key Country Dynamics
      • 11.3.2.2. Target Disease Prevalence
      • 11.3.2.3. Regulatory Framework
      • 11.3.2.4. Reimbursement Framework
      • 11.3.2.5. Uk Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.3. Germany
      • 11.3.3.1. Key Country Dynamics
      • 11.3.3.2. Target Disease Prevalence
      • 11.3.3.3. Regulatory Framework
      • 11.3.3.4. Reimbursement Framework
      • 11.3.3.5. Germany Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.4. France
      • 11.3.4.1. Key Country Dynamics
      • 11.3.4.2. Target Disease Prevalence
      • 11.3.4.3. Regulatory Framework
      • 11.3.4.4. Reimbursement Framework
      • 11.3.4.5. France Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.5. Italy
      • 11.3.5.1. Key Country Dynamics
      • 11.3.5.2. Target Disease Prevalence
      • 11.3.5.3. Regulatory Framework
      • 11.3.5.4. Reimbursement Framework
      • 11.3.5.5. Italy Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.6. Spain
      • 11.3.6.1. Key Country Dynamics
      • 11.3.6.2. Target Disease Prevalence
      • 11.3.6.3. Regulatory Framework
      • 11.3.6.4. Reimbursement Framework
      • 11.3.6.5. Spain Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.7. Denmark
      • 11.3.7.1. Key Country Dynamics
      • 11.3.7.2. Target Disease Prevalence
      • 11.3.7.3. Regulatory Framework
      • 11.3.7.4. Reimbursement Framework
      • 11.3.7.5. Denmark Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.8. Sweden
      • 11.3.8.1. Key Country Dynamics
      • 11.3.8.2. Target Disease Prevalence
      • 11.3.8.3. Regulatory Framework
      • 11.3.8.4. Reimbursement Framework
      • 11.3.8.5. Sweden Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.3.9. Norway
      • 11.3.9.1. Key Country Dynamics
      • 11.3.9.2. Target Disease Prevalence
      • 11.3.9.3. Regulatory Framework
      • 11.3.9.4. Reimbursement Framework
      • 11.3.9.5. Norway Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4. Asia Pacific
    • 11.4.1. Asia Pacific Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.2. Japan
      • 11.4.2.1. Key Country Dynamics
      • 11.4.2.2. Target Disease Prevalence
      • 11.4.2.3. Regulatory Framework
      • 11.4.2.4. Reimbursement Framework
      • 11.4.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.3. China
      • 11.4.3.1. Key Country Dynamics
      • 11.4.3.2. Target Disease Prevalence
      • 11.4.3.3. Regulatory Framework
      • 11.4.3.4. Reimbursement Framework
      • 11.4.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.4. India
      • 11.4.4.1. Key Country Dynamics
      • 11.4.4.2. Target Disease Prevalence
      • 11.4.4.3. Regulatory Framework
      • 11.4.4.4. Reimbursement Framework
      • 11.4.4.5. India Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.5. Australia
      • 11.4.5.1. Key Country Dynamics
      • 11.4.5.2. Target Disease Prevalence
      • 11.4.5.3. Regulatory Framework
      • 11.4.5.4. Reimbursement Framework
      • 11.4.5.5. Australia Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.6. South Korea
      • 11.4.6.1. Key Country Dynamics
      • 11.4.6.2. Target Disease Prevalence
      • 11.4.6.3. Regulatory Framework
      • 11.4.6.4. Reimbursement Framework
      • 11.4.6.5. South Korea Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.4.7. Thailand
      • 11.4.7.1. Key Country Dynamics
      • 11.4.7.2. Target Disease Prevalence
      • 11.4.7.3. Regulatory Framework
      • 11.4.7.4. Reimbursement Framework
      • 11.4.7.5. Thailand Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.5. Latin America
    • 11.5.1. Latin America Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.5.2. Brazil
      • 11.5.2.1. Key Country Dynamics
      • 11.5.2.2. Target Disease Prevalence
      • 11.5.2.3. Regulatory Framework
      • 11.5.2.4. Reimbursement Framework
      • 11.5.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.5.3. Argentina
      • 11.5.3.1. Key Country Dynamics
      • 11.5.3.2. Target Disease Prevalence
      • 11.5.3.3. Regulatory Framework
      • 11.5.3.4. Reimbursement Framework
      • 11.5.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Middle East and Africa Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.6.2. South Africa
      • 11.6.2.1. Key Country Dynamics
      • 11.6.2.2. Target Disease Prevalence
      • 11.6.2.3. Regulatory Framework
      • 11.6.2.4. Reimbursement Framework
      • 11.6.2.5. South Africa Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.6.3. Saudi Arabia
      • 11.6.3.1. Key Country Dynamics
      • 11.6.3.2. Target Disease Prevalence
      • 11.6.3.3. Regulatory Framework
      • 11.6.3.4. Reimbursement Framework
      • 11.6.3.5. Saudi Arabia Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.6.4. UAE
      • 11.6.4.1. Key Country Dynamics
      • 11.6.4.2. Target Disease Prevalence
      • 11.6.4.3. Regulatory Framework
      • 11.6.4.4. Reimbursement Framework
      • 11.6.4.5. UAE Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.6.5. Kuwait
      • 11.6.5.1. Key Country Dynamics
      • 11.6.5.2. Target Disease Prevalence
      • 11.6.5.3. Regulatory Framework
      • 11.6.5.4. Reimbursement Framework
      • 11.6.5.5. Kuwait Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 12. Competitive Landscape

  • 12.1. Recent Developments & Impact Analysis by Key Market Participants
  • 12.2. Company Categorization
  • 12.3. Participant Overview
  • 12.4. Financial Performance
  • 12.5. Product Bench Marking
  • 12.6. Company Market Share Analysis, 2024
  • 12.7. Company Profiles
    • 12.7.1. F. Hoffmann-La Roche Ltd
      • 12.7.1.1. Participant's Overview
      • 12.7.1.2. Financial Performance
      • 12.7.1.3. Product Benchmarking
      • 12.7.1.4. Recent Developments/ Strategic Initiatives
    • 12.7.2. Novartis AG
      • 12.7.2.1. Participant's Overview
      • 12.7.2.2. Financial Performance
      • 12.7.2.3. Product Benchmarking
      • 12.7.2.4. Recent Developments/ Strategic Initiatives
    • 12.7.3. AbbVie Inc.
      • 12.7.3.1. Participant's Overview
      • 12.7.3.2. Financial Performance
      • 12.7.3.3. Product Benchmarking
      • 12.7.3.4. Recent Developments/ Strategic Initiatives
    • 12.7.4. Johnson & Johnson Services, Inc.
      • 12.7.4.1. Participant's Overview
      • 12.7.4.2. Financial Performance
      • 12.7.4.3. Product Benchmarking
      • 12.7.4.4. Recent Developments/ Strategic Initiatives
    • 12.7.5. Merck & Co., Inc.
      • 12.7.5.1. Participant's Overview
      • 12.7.5.2. Financial Performance
      • 12.7.5.3. Product Benchmarking
      • 12.7.5.4. Recent Developments/ Strategic Initiatives
    • 12.7.6. Pfizer Inc.
      • 12.7.6.1. Participant's Overview
      • 12.7.6.2. Financial Performance
      • 12.7.6.3. Product Benchmarking
      • 12.7.6.4. Recent Developments/ Strategic Initiatives
    • 12.7.7. Bristol-Myers Squibb Company
      • 12.7.7.1. Participant's Overview
      • 12.7.7.2. Financial Performance
      • 12.7.7.3. Product Benchmarking
      • 12.7.7.4. Recent Developments/ Strategic Initiatives
    • 12.7.8. Sanofi
      • 12.7.8.1. Participant's Overview
      • 12.7.8.2. Financial Performance
      • 12.7.8.3. Product Benchmarking
      • 12.7.8.4. Recent Developments/ Strategic Initiatives
    • 12.7.9. GlaxoSmithKline plc.
      • 12.7.9.1. Participant's Overview
      • 12.7.9.2. Financial Performance
      • 12.7.9.3. Product Benchmarking
      • 12.7.9.4. Recent Developments/ Strategic Initiatives
    • 12.7.10. AstraZeneca
      • 12.7.10.1. Participant's Overview
      • 12.7.10.2. Financial Performance
      • 12.7.10.3. Product Benchmarking
      • 12.7.10.4. Recent Developments/ Strategic Initiatives
    • 12.7.11. Takeda Pharmaceutical Co., Ltd.
      • 12.7.11.1. Participant's Overview
      • 12.7.11.2. Financial Performance
      • 12.7.11.3. Product Benchmarking
      • 12.7.11.4. Recent Developments/ Strategic Initiatives

Chapter 13. Conclusion

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 4 Global Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 5 Global Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 6 Global Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 7 Global Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 8 Global Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 9 Global Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 10 North America Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 11 North America Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 12 North America Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 13 North America Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 14 North America Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 15 North America Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 16 North America Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 17 North America Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 18 U.S. Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 19 U.S. Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 20 U.S. Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 21 U.S. Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 22 U.S. Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 23 U.S. Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 24 U.S. Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 25 Canada Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 26 Canada Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 27 Canada Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 28 Canada Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 29 Canada Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 30 Canada Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 31 Canada Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 32 Europe Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 33 Europe Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 34 Europe Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 35 Europe Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 36 Europe Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 37 Europe Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 38 Europe Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 39 Europe Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 40 Germany Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 41 Germany Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 42 Germany Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 43 Germany Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 44 Germany Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 45 Germany Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 46 Germany Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 47 UK Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 48 UK Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 49 UK Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 50 UK Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 51 UK Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 52 UK Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 53 UK Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 54 France Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 55 France Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 56 France Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 57 France Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 58 France Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 59 France Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 60 France Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 61 Italy Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 62 Italy Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 63 Italy Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 64 Italy Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 65 Italy Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 66 Italy Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 67 Italy Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 68 Spain Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 69 Spain Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 70 Spain Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 71 Spain Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 72 Spain Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 73 Spain Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 74 Spain Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 75 Asia Pacific Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 76 Asia Pacific Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 77 Asia Pacific Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 78 Asia Pacific Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 79 Asia Pacific Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 80 Asia Pacific Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 81 Asia Pacific Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 82 Asia Pacific Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 83 China Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 84 China Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 85 China Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 86 China Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 87 China Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 88 China Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 89 China Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 90 Japan Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 91 Japan Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 92 Japan Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 93 Japan Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 94 Japan Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 95 Japan Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 96 Japan Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 97 India Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 98 India Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 99 India Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 100 India Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 101 India Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 102 India Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 103 India Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 104 Middle East Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 105 Middle East Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 106 Middle East Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 107 Middle East Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 108 Middle East Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 109 Middle East Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 110 Middle East Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 111 Middle East Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 112 Saudi Arabia Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 113 Saudi Arabia Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 114 Saudi Arabia Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 115 Saudi Arabia Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 116 Saudi Arabia Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 117 Saudi Arabia Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 118 Saudi Arabia Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 119 UAE Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 120 UAE Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 121 UAE Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 122 UAE Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 123 UAE Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 124 UAE Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 125 UAE Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 126 Kuwait Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 127 Kuwait Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 128 Kuwait Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 129 Kuwait Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 130 Kuwait Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 131 Kuwait Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 132 Kuwait Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Pharmaceutical Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Pharmaceutical market: Molecule type outlook and key takeaways
  • Fig. 15 Pharmaceutical market: Molecule type movement analysis & market share 2024 & 2030
  • Fig. 16 Biologics & biosimilars (large molecules) market, 2018 - 2030 (USD Billion)
  • Fig. 17 Monoclonal Antibodies market, 2018 - 2030 (USD Billion)
  • Fig. 18 Vaccines market, 2018 - 2030 (USD Billion)
  • Fig. 19 Cell & Gene Therapy market, 2018 - 2030 (USD Billion)
  • Fig. 20 Others market, 2018 - 2030 (USD Billion)
  • Fig. 21 Conventional drugs (small molecules) market, 2018 - 2030 (USD Billion)
  • Fig. 22 Pharmaceutical market: Product outlook and key takeaways
  • Fig. 23 Pharmaceutical market: Product movement analysis & market share 2024 & 2030
  • Fig. 24 Branded pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 25 Generics pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 26 Pharmaceutical market: Type outlook and key takeaways
  • Fig. 27 Pharmaceutical market: Type movement analysis & market share 2024 & 2030
  • Fig. 28 Prescription pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 29 OTC pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 30 Pharmaceutical market: Disease outlook and key takeaways
  • Fig. 31 Pharmaceutical market: Disease movement analysis & market share 2024 & 2030
  • Fig. 32 Cancer market, 2018 - 2030 (USD Billion)
  • Fig. 33 Cardiovascular diseases market, 2018 - 2030 (USD Billion)
  • Fig. 34 Diabetes market, 2018 - 2030 (USD Billion)
  • Fig. 35 Infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig. 36 Neurological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 37 Respiratory diseases market, 2018 - 2030 (USD Billion)
  • Fig. 38 Autoimmune diseases market, 2018 - 2030 (USD Billion)
  • Fig. 39 Mental health disorders market, 2018 - 2030 (USD Billion)
  • Fig. 40 Gastrointestinal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 41 Women's health diseases market, 2018 - 2030 (USD Billion)
  • Fig. 42 Genetic and rare genetic diseases market, 2018 - 2030 (USD Billion)
  • Fig. 43 Dermatological conditions market, 2018 - 2030 (USD Billion)
  • Fig. 44 Obesity market, 2018 - 2030 (USD Billion)
  • Fig. 45 Renal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 46 Liver conditions market, 2018 - 2030 (USD Billion)
  • Fig. 47 Hemotological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 48 Eye conditions market, 2018 - 2030 (USD Billion)
  • Fig. 49 Infertility conditions market, 2018 - 2030 (USD Billion)
  • Fig. 50 Endocrine disorders market, 2018 - 2030 (USD Billion)
  • Fig. 51 Allergies market, 2018 - 2030 (USD Billion)
  • Fig. 52 Other diseases market, 2018 - 2030 (USD Billion)
  • Fig. 53 Pharmaceutical market: Route of administration outlook and key takeaways
  • Fig. 54 Pharmaceutical market: Route of administration movement analysis & market share 2024 & 2030
  • Fig. 55 Oral pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 56 Tablets pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 57 Capsules pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 58 Suspensions pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 59 Others formulation pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 60 Topical pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 61 Parenteral pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 62 Intravenous market, 2018 - 2030 (USD Billion)
  • Fig. 63 Intramuscular market, 2018 - 2030 (USD Billion)
  • Fig. 64 Inhalations pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 65 Others pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 66 Pharmaceutical market: Age group outlook and key takeaways
  • Fig. 67 Pharmaceutical market: Age group movement analysis & market share 2024 & 2030
  • Fig. 68 Children & Adolescents pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 69 Adults pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 70 Geriatric pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 71 Pharmaceutical market: Distribution Channel outlook and key takeaways
  • Fig. 72 Pharmaceutical market: Distribution Channel movement analysis & market share 2024 & 2030
  • Fig. 73 Hospital Pharmacy pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 74 Retail Pharmacy pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 75 Others pharmaceutical market, 2018 - 2030 (USD Billion
  • Fig. 76 Regional Outlook, 2024 & 2030
  • Fig. 77 Regional Market Dashboard
  • Fig. 78 Regional Market Place: Key Takeaways
  • Fig. 79 North America
  • Fig. 80 North America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 81 U.S. Key Country Dynamics
  • Fig. 82 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 83 Canada Key Country Dynamics
  • Fig. 84 Canada Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 Mexico Key Country Dynamics
  • Fig. 86 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Europe
  • Fig. 88 Europe Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 UK Key Country Dynamics
  • Fig. 90 UK Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 91 Germany Key Country Dynamics
  • Fig. 92 Germany Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 93 France Key Country Dynamics
  • Fig. 94 France Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 95 Italy Key Country Dynamics
  • Fig. 96 Italy Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 97 Spain Key Country Dynamics
  • Fig. 98 Spain Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 99 Denmark Key Country Dynamics
  • Fig. 100 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 101 Sweden Key Country Dynamics
  • Fig. 102 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 103 Norway Key Country Dynamics
  • Fig. 104 Norway Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 105 Asia Pacific
  • Fig. 106 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 107 Japan Key Country Dynamics
  • Fig. 108 Japan Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 109 China Key Country Dynamics
  • Fig. 110 China Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 111 India Key Country Dynamics
  • Fig. 112 India Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 113 Australia Key Country Dynamics
  • Fig. 114 Australia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 115 Thailand Key Country Dynamics
  • Fig. 116 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 117 South Korea Key Country Dynamics
  • Fig. 118 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 119 Latin America
  • Fig. 120 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 121 Brazil Key Country Dynamics
  • Fig. 122 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 123 Argentina Key Country Dynamics
  • Fig. 124 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 125 MEA
  • Fig. 126 MEA Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 127 South Africa Key Country Dynamics
  • Fig. 128 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 129 Saudi Arabia Key Country Dynamics
  • Fig. 130 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 131 UAE Key Country Dynamics
  • Fig. 132 UAE Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 133 Kuwait Key Country Dynamics
  • Fig. 134 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 135 Strategy Mapping